Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Kits > CD30 > EP-135

CD30 [Biotinylated] : CD30L Inhibitor Screening ELISA Kit

For research use only.

Order Now

EP135-C01High-bind Plate1 plate
EP135-C02Human CD30L15 μg
EP135-C03Biotinylated Human CD3010 μg
EP135-C04Anti-CD30 Neutralizing Antibody20 μg
EP135-C05Streptavidin-HRP10 μg
EP135-C06Coating Buffer12 mL
EP135-C0710xWashing Buffer 50 mL
EP135-C08Blocking Buffer50 mL
EP135-C09Substrate Solution12 mL
EP135-C10Stop Solution7 mL
  • Background
    CD30 belongs to the tumor necrosis factor receptor (TNFR) superfamily, and the physiological functions of CD30 are in addition to the transmission of synergistic stimulation signals. CD30 ligand (CD30L) belongs to the tumor necrosis factor (TNF) superfamily, and CD30L is present in activated T cells, quiescent B cells, granulocytes, thymic medullary cells, and various leukemia cells. After crosslinking CD30 and CD30L, diverse physiological function signaling is led by TNFR correlation factors (TRAF), including TRAF1, 2, 3, 5. CD30 was originally found in Hodgkins lymphoma and Reed Sternberg (RS) cells, and is now known to be expressed on the surface of some normal lymphocytes, virally infected lymphocytes, lymphocytes of lymphogenetic origin, and activated T cell subsets that produce Th2 cytokines.
  • Application
    This kit is developed for screening for inhibitors of human CD30 binding to human CD30L.

    It is for research use only.

  • Reconstitution
    Please see Certificate of Analysis for details of reconstitution instruction and specific concentration.
  • Storage
    The unopened kit is stable for 12 months from the date of manufacture if stored at 2°C to 8°C.

    The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.

  • Assay Principles
    This inhibitor screening ELISA kit is designed to facilitate the identification and characterization of new CD30 pathway inhibitors. The assay takes advantage of our in house-developed binding of biotinylated human CD30 to immobilized human CD30 Ligand in a functional ELISA assay, and employs a simple colorimetric ELISA platform. Briefly, we provide you with a human Biotinylated CD30 protein, a human CD30 Ligand protein, an anti-CD30 neutralizing antibody (as method verified Std.), and Streptavidin-HRP reagent.

    Your experiment will include 4 simple steps:

    a) Coat the plate with human CD30 Ligand.

    b) Add your molecule of interest to the tests.

    c) Add human CD30-Biotin to bind the coated CD30 Ligand.

    d) Add Streptavidin-HRP followed by TMB or other colorimetric HRP substrate.

    Finally, the half maximal inhibitory concentration (IC50) of your compound to CD30 Ligand: CD30 binding will be determined by comparing OD readings among different experimental groups.

Typical Data

Serial dilutions of Anti-CD30 Neutralizing antibody (Catalog # EP135-C04) (1:1 serial dilution, from 5 μg/mL to 0.019μg/mL) was added into Biotinylated CD30: CD30L binding reactions. The assay was performed according to the protocol described below. Background was subtracted from data points prior to log transformation and curve fitting (QC tested).

Comments (0)

ETD of in-stock products: 2 business days

Price(USD) : $650.00

Promotion & Exhibitions

Drug Development Status

  • Number of Launched Drugs:1 Details
  • Number of Drugs in Clinical Trials:17 Details
  • Latest Research Phase:Approved

Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

Related Products

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message